Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more.
作者信息
Rotte Anand
机构信息
Department of Clinical and Regulatory Affairs, Arcellx Inc, Redwood City, CA, United States.
出版信息
Front Oncol. 2024 Apr 15;14:1404376. doi: 10.3389/fonc.2024.1404376. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more.社论：细胞疗法的新进展：新型结合域、通用型嵌合抗原受体T细胞等等。
Front Oncol. 2024 Apr 15;14:1404376. doi: 10.3389/fonc.2024.1404376. eCollection 2024.
2
A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models.一种具有新型 DAP10/DAP12 信号结构域的人源化 Lym-1 CAR，在 B 细胞淋巴瘤模型中表现出降低的连续信号和增强的抗肿瘤活性。
Clin Cancer Res. 2020 Jul 15;26(14):3694-3706. doi: 10.1158/1078-0432.CCR-19-3417. Epub 2020 Apr 9.
3
The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR.嵌合抗原受体 T 细胞（CAR-T 细胞）的持久性和抗肿瘤疗效受 CDR 内的持续信号调节。
Int Immunopharmacol. 2024 Jan 5;126:111239. doi: 10.1016/j.intimp.2023.111239. Epub 2023 Nov 17.
4
GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation against spp. And had difference in the strength of tonic signaling.GXMR-CAR 包含独特的 GXM 特异性单链可变片段 (scFv)，介导针对 spp. 的细胞激活，并在持续信号强度上存在差异。
Bioengineered. 2023 Dec;14(1):2281059. doi: 10.1080/21655979.2023.2281059. Epub 2023 Nov 18.
5
Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness.嵌合抗原受体的电荷密度调节优化了持续信号和 CAR-T 细胞的适应性。
Cell Res. 2023 May;33(5):341-354. doi: 10.1038/s41422-023-00789-0. Epub 2023 Mar 8.
6
The Emergence of Universal Immune Receptor T Cell Therapy for Cancer.癌症通用免疫受体T细胞疗法的出现。
Front Oncol. 2019 Mar 26;9:176. doi: 10.3389/fonc.2019.00176. eCollection 2019.
7
Analysis of CAR-Mediated Tonic Signaling.嵌合抗原受体（CAR）介导的张力信号分析。
Methods Mol Biol. 2020;2086:223-236. doi: 10.1007/978-1-0716-0146-4_17.
8
Tonic Signaling and Its Effects on Lymphopoiesis of CAR-Armed Hematopoietic Stem and Progenitor Cells.激动信号及其对 CAR 武装造血干/祖细胞的淋巴样分化的影响。
J Immunol. 2019 Mar 15;202(6):1735-1746. doi: 10.4049/jimmunol.1801004. Epub 2019 Feb 6.
9
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.用于通用肿瘤靶向的mSA2亲和力增强的生物素结合嵌合抗原受体T细胞。
Oncoimmunology. 2017 Oct 26;7(1):e1368604. doi: 10.1080/2162402X.2017.1368604. eCollection 2017.
10
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.CRISPR/Cas9技术构建的通用型CD19/CD22双靶点嵌合抗原受体T细胞疗法治疗复发/难治性B细胞急性淋巴细胞白血病
Clin Cancer Res. 2021 May 15;27(10):2764-2772. doi: 10.1158/1078-0432.CCR-20-3863. Epub 2021 Feb 24.
本文引用的文献
1
Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary.抗PD-1单药治疗或抗PD-1与伊匹木单抗联合治疗患者的反应和生存预测模型：编辑评论
Ann Transl Med. 2023 Mar 15;11(5):227. doi: 10.21037/atm-22-6564. Epub 2023 Jan 27.
2
Dose-response correlation for CAR-T cells: a systematic review of clinical studies.CAR-T 细胞的剂量反应相关性：临床研究的系统评价。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005678.
3
Next generations of CAR-T cells - new therapeutic opportunities in hematology?下一代嵌合抗原受体 T 细胞 - 血液学中的新治疗机会？
Front Immunol. 2022 Oct 28;13:1034707. doi: 10.3389/fimmu.2022.1034707. eCollection 2022.
4
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy.CAR T 细胞疗法的世代、批准和临床试验的最新进展。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2114254. doi: 10.1080/21645515.2022.2114254. Epub 2022 Sep 12.
5
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.嵌合抗原受体 T 细胞（CAR-T）疗法在肺癌中的效用和缺陷。
Front Immunol. 2022 Jun 2;13:903562. doi: 10.3389/fimmu.2022.903562. eCollection 2022.
6
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.嵌合抗原受体（CAR）在癌症免疫疗法中的竞赛：从 CAR T、CAR NK 到 CAR 巨噬细胞疗法。
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119. doi: 10.1186/s13046-022-02327-z.
7
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.基于药理学的抗癌药物排名，以指导癌症免疫治疗联合用药的临床开发。
J Exp Clin Cancer Res. 2021 Oct 1;40(1):311. doi: 10.1186/s13046-021-02111-5.
8
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.靶向TIGIT用于癌症免疫治疗：临床进展更新
Biomedicines. 2021 Sep 21;9(9):1277. doi: 10.3390/biomedicines9091277.
9
Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.复合 CD79A/CD40 共刺激内源性结构域增强了 CD19CAR-T 细胞的增殖和存活。
Mol Ther. 2021 Sep 1;29(9):2677-2690. doi: 10.1016/j.ymthe.2021.04.038. Epub 2021 May 1.
10
Phage display targeting identifies EYA1 as a regulator of glioblastoma stem cell maintenance and proliferation.噬菌体展示技术靶向鉴定 EYA1 为神经胶质瘤干细胞维持和增殖的调控因子。
Stem Cells. 2021 Jul;39(7):853-865. doi: 10.1002/stem.3355. Epub 2021 Mar 4.
Zotero 插件